Compared to Estimates, Hologic (HOLX) Q3 Earnings: A Look at Key Metrics

Core Insights - Hologic reported revenue of $1.01 billion for the quarter ended June 2024, reflecting a year-over-year increase of 2.7% and an EPS of $1.06 compared to $0.93 in the same quarter last year [5] Revenue Performance - GYN Surgical revenue was $166.60 million, slightly below the estimated $166.70 million, marking a year-over-year increase of +5.9% [3] - Total Diagnostics revenue reached $440.80 million, exceeding the average estimate of $433.13 million, with a year-over-year change of +0.3% [3] - Total Breast Health revenue was $385 million, surpassing the estimated $375.60 million, representing a +6.9% change year over year [3] - Skeletal Health revenue was $19 million, significantly below the estimated $25.26 million, showing a -29.9% change compared to the previous year [3] - Breast Imaging revenue was $309.20 million, exceeding the estimate of $296.11 million, with an +8.1% year-over-year change [3] - Blood Screening revenue was $7.90 million, above the estimate of $7.08 million, but down -26.2% year over year [3] - Molecular Diagnostics revenue was $310.70 million, slightly above the estimate of $308.09 million, with a +2.8% year-over-year change [3] - Cytology and Perinatal revenue was $122.20 million, exceeding the estimate of $119.54 million, but down -3.6% year over year [3] - Interventional Breast Solutions revenue was $75.80 million, below the estimate of $77.53 million, with a +2.2% year-over-year change [3] Stock Performance - Hologic shares have returned +5.9% over the past month, outperforming the Zacks S&P 500 composite, which saw a -0.2% change [4] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [4]